Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Reaches New 12-Month Low – Here’s Why

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)’s stock price reached a new 52-week low during trading on Wednesday . The company traded as low as $21.18 and last traded at $21.4050, with a volume of 1371814 shares traded. The stock had previously closed at $22.88.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Zacks Research lowered Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Truist Financial set a $28.00 price objective on Fresenius Medical Care AG & Co. KGaA in a research note on Monday, January 5th. Wall Street Zen upgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Bank of America lowered shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a report on Wednesday, October 15th. Finally, UBS Group downgraded Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a research report on Wednesday, October 15th. Three research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $28.00.

Fresenius Medical Care AG & Co. KGaA Stock Performance

The firm has a 50-day moving average of $23.52 and a two-hundred day moving average of $25.17. The company has a market capitalization of $12.56 billion, a PE ratio of 15.62, a PEG ratio of 0.73 and a beta of 0.90. The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 0.45.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.05. The business had revenue of $5.73 billion during the quarter, compared to analysts’ expectations of $4.72 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 7.42% and a net margin of 3.72%. Research analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. TD Waterhouse Canada Inc. acquired a new stake in Fresenius Medical Care AG & Co. KGaA in the second quarter valued at $36,000. CIBC Private Wealth Group LLC raised its stake in Fresenius Medical Care AG & Co. KGaA by 398.2% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock valued at $36,000 after purchasing an additional 1,103 shares during the last quarter. Atlantic Union Bankshares Corp purchased a new position in shares of Fresenius Medical Care AG & Co. KGaA during the second quarter valued at approximately $43,000. Hantz Financial Services Inc. lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 568.5% during the 2nd quarter. Hantz Financial Services Inc. now owns 2,079 shares of the company’s stock worth $59,000 after purchasing an additional 1,768 shares during the period. Finally, Huntington National Bank grew its holdings in Fresenius Medical Care AG & Co. KGaA by 219.5% in the 2nd quarter. Huntington National Bank now owns 2,355 shares of the company’s stock valued at $67,000 after buying an additional 1,618 shares during the period. Institutional investors and hedge funds own 8.37% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.